Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease

Turkish Journal of Gastroenterology

Volumn 30, Issue 8, 2019, Pages 680-685

  Fan, Hua ^a   Du, Juan ^b   Liu, Xia ^a   Zheng, Wei Wei ^a   Zhuang, Ze Hao ^a   Wang, Cheng Dang ^a   Gao, Rui ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Mechatronic Engineering Department   (China)

Author keywords

Inflammatory bowel disease; Microflora structure; Pentasa; Probiotics; Prognosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 4; INTERLEUKIN 6; LACTOFERRIN; MESALAZINE; PROBIOTIC AGENT; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BACTERIAL COUNT; BACTEROIDES; BIFIDOBACTERIUM; CLINICAL ARTICLE; COMMUNITY STRUCTURE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ENTEROBACTERIACEAE; ENTEROCOCCUS; FECES LEVEL; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LACTOBACILLUS; MALE; NAUSEA; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; SACCHAROMYCES; ULCERATIVE COLITIS; ULCERATIVE COLITIS ACTIVITY INDEX; VOMITING; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECT; FECES; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DRUG THERAPY, COMBINATION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; PROGNOSIS; TREATMENT OUTCOME;

EID: 85071544525     PISSN: 13004948     EISSN: 21485607     Source Type: Journal    
DOI: 10.5152/tjg.2019.18426     Document Type: Article

References (24)

1. Rhodes J, Thomas G, Evans BK. Inflammatory Bowel Disease Management. Drugs 1997; 53: 189-94. [CrossRef]
2. Zurek M, Kern I, Manuwald U, et al. Epidemiology and care structures for children and adolescents and young adults up to the 26th year of life with inflammatory bowel diseases (IBD) in Leipzig/Saxony/Germany. J Public Health 2018: 1-6. [CrossRef]
3. Chadwick VS, Chen W. The intestinal microflora and inflammatory bowel disease. Medical Importance of the Normal Microflora. Kluwer Academic Publishers, Dordrecht, The Netherlands. 1999; 177-221. [CrossRef]
4. Bamias G, Pizarro T, Cominelli F. New Paradigms in the Pathogenesis of IBD. Inflamm Bowel Dis 2011: 41-57. [CrossRef]
5. Dong X, Ye X, Chen X, et al. Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease. Dig Dis Sci 2014; 59: 769-77. [CrossRef]
6. Hong HJ, Kim J, Yong JS, Kim D, Roh KM, Kang I. pH-Sensitive mesalazine carrier for colon-targeted drug delivery: A two-fold composition of mesalazine with a clay and alginate. Macromolecular Res 2017; 25: 1145-52. [CrossRef]
7. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol 2011; 2: 94. [CrossRef]
8. Chandler M, Wollins E, Toles A, Borum M, Doman DB. The emerging therapeutic role of probiotics in inflammatory bowel disease. Gastroenterol Hepatol 2008; 4: 634-40.
9. Khanna PV, Shih DQ, Haritunians T, McGovern DP, Targan S. Use of animal models in elucidating disease pathogenesis in IBD. Semin Immunopathol 2014; 36: 541-51. [CrossRef]
10. Kamp KJ, Brittain K. Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review. Patient 2018: 1-14. [CrossRef]
11. Munkholm P, Pedersen N. Evaluation of Quality of Life in Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2012: 333-40. [CrossRef]
12. Andre MF, Aumaitre O, Piette JC, et al. Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease. Dig Dis Sci 2008; 53: 490-9. [CrossRef]
13. Liu ZJ. New progress in the pathogenesis of inflammatory bowel disease. J Intern Med Concepts Prac 2013; 8: 5-8.
14. Ihara S, Hirata Y, Koike K. TGF-beta in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol 2017; 52: 777-87. [CrossRef]
15. Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol 2016; 51: 11-21. [CrossRef]
16. Fujimori S, Sakamoto C. Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora. Clin J Gastroenterol 2013; 6: 345-51. [CrossRef]
17. Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV. Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA J 2015; 6: 14. [CrossRef]
18. Mokrozub VV, Lazarenko LM, Sichel LM, et al. The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA J 2015; 6: 13. [CrossRef]
19. He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci 2017; 7: 54. [CrossRef]
20. Bjerrum JT, Wang Y, Hao F, et al. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics 2015; 11: 122-33. [CrossRef]
21. Longhi MS, Moss A, Jiang ZG, Robson SC. Purinergic signaling during intestinal inflammation. J Mol Med 2017; 95: 915-25. [CrossRef]
22. Zhang Z, Liu Z. Paneth cells: the hub for sensing and regulating intestinal flora. Sci China Life Sci 2016; 59: 463-7. [CrossRef]
23. Hill DA, Jr WAF. The Intestinal Immune System during Homeostasis and Inflammatory Bowel Disease. Inflamm Bowel Dis 2017: 15-30. [CrossRef]
24. Curnow SJ, Scheeltoellner D, Jenkinson W, et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 2004; 173: 5290-7. [CrossRef]